Most investors missed the warning signs in the Novo‑Hims saga – and that cost them.
After ending a similar agreement last year over patent concerns, Novo is now back on the Hims platform. The move reflects a strategic pivot: instead of fighting a losing battle in the courtroom, Novo chooses to monetize the channel while tightening IP controls. By licensing its flagship GLP‑1 drugs—Ozempic and Wegovy—to a fast‑growing telehealth brand, Novo taps into a distribution network that reaches millennials and Gen‑Z consumers who prefer digital prescriptions. This could translate into a new, recurring revenue stream estimated at $5‑$6 billion over the next five years, assuming a 10% market capture of the projected 25 million U.S. users.
The telehealth space has been a battleground for weight‑loss drug access. Hims & Hers surged nearly 40% in after‑hours trading, indicating that retail investors view the deal as a catalyst for growth. Competitors such as Tata Health in India and Adani Health in the Middle East are expanding their own digital formularies, but none have secured a direct licensing deal with a GLP‑1 giant. If Novo’s partnership proves seamless, it could force rivals to renegotiate their own agreements or risk losing market share to a more compliant, brand‑aligned offering.
In February, Hims launched a $49 copycat version of Novo’s obesity pill, prompting a patent infringement lawsuit. The legal wrangling caused a temporary dip in Hims’ stock and raised concerns about the integrity of compounded GLP‑1 products. Historically, similar disputes—such as the 2019 AbbVie‑Mylan case over Humira biosimilars—led to settlement agreements that opened new sales channels while preserving the original holder’s margins. The precedent suggests that Novo’s current approach may be a calculated compromise: enforce IP rights, then license under stricter terms.
GLP‑1 (glucagon‑like peptide‑1) agonists stimulate insulin secretion and curb appetite, making them the most effective pharmacological tools for obesity and type‑2 diabetes. Patents typically cover the active ingredient’s molecular structure and specific formulation processes. When a third party creates a “compounded” version, it must either obtain a licensing agreement or risk infringement. Compounded drugs often skirt FDA approval pathways, leading to variability in efficacy and safety—a key reason why Novo labeled Hims’ earlier offerings as “egregious.”
Investment banks now project that 25 million Americans will be on GLP‑1 therapies by the end of the decade, up from roughly 5 million today. The drivers are threefold: oral GLP‑1 formulations entering the market, broader insurance coverage, and a stabilized global supply chain. This exponential growth translates into an estimated $30‑$40 billion market size. Companies that secure early digital distribution rights, like Novo with Hims, stand to capture a disproportionate share of this upside. Conversely, firms that remain locked out of telehealth channels may see slower top‑line growth despite strong product pipelines.
Bull Case: The partnership unlocks a high‑margin, subscription‑style revenue stream. Novo’s IP enforcement strengthens brand equity, and the telehealth channel accelerates patient acquisition, driving earnings per share (EPS) expansion of 12‑15% over the next two years. Hims benefits from premium pricing power, supporting its valuation multiple expansion.
Bear Case: Ongoing legal disputes could resurface, exposing Novo to royalty reductions or costly settlements. If regulatory scrutiny tightens around compounded GLP‑1 products, Hims may face sales restrictions, eroding the anticipated revenue boost. Additionally, any supply constraints could force Novo to prioritize traditional pharmacy channels, limiting the partnership’s upside.
Bottom line: The Novo‑Hims alliance is a high‑stakes gamble that could redefine how GLP‑1 drugs reach patients. For investors, the key is to weigh the near‑term volatility against the long‑term upside of a $30 billion market in rapid expansion.